- Home
- ELWS vs NXTC Comparison
ELWS vs NXTC Comparison
Compare ELWS & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELWS
- NXTC
- Stock Information
- Founded
- ELWS 2018
- NXTC 2015
- Country
- ELWS Japan
- NXTC United States
- Employees
- ELWS N/A
- NXTC N/A
- Industry
- ELWS
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- ELWS
- NXTC Health Care
- Exchange
- ELWS Nasdaq
- NXTC Nasdaq
- Market Cap
- ELWS 12.1M
- NXTC 13.9M
- IPO Year
- ELWS 2023
- NXTC 2019
- Fundamental
- Price
- ELWS $4.18
- NXTC $4.80
- Analyst Decision
- ELWS
- NXTC Strong Buy
- Analyst Count
- ELWS 0
- NXTC 2
- Target Price
- ELWS N/A
- NXTC $25.50
- AVG Volume (30 Days)
- ELWS 392.6K
- NXTC 325.3K
- Earning Date
- ELWS 08-19-2025
- NXTC 08-07-2025
- Dividend Yield
- ELWS N/A
- NXTC N/A
- EPS Growth
- ELWS N/A
- NXTC N/A
- EPS
- ELWS N/A
- NXTC N/A
- Revenue
- ELWS $3,069,669.00
- NXTC N/A
- Revenue This Year
- ELWS N/A
- NXTC N/A
- Revenue Next Year
- ELWS N/A
- NXTC N/A
- P/E Ratio
- ELWS N/A
- NXTC N/A
- Revenue Growth
- ELWS 144.46
- NXTC N/A
- 52 Week Low
- ELWS $1.04
- NXTC $2.69
- 52 Week High
- ELWS $10.50
- NXTC $20.16
- Technical
- Relative Strength Index (RSI)
- ELWS 51.37
- NXTC 42.50
- Support Level
- ELWS $3.50
- NXTC $4.75
- Resistance Level
- ELWS $10.50
- NXTC $5.42
- Average True Range (ATR)
- ELWS 1.53
- NXTC 0.43
- MACD
- ELWS -0.01
- NXTC -0.01
- Stochastic Oscillator
- ELWS 24.58
- NXTC 2.99
About ELWS Earlyworks Co. Ltd.
Earlyworks Co Ltd is a blockchain-based technology company. It builds products, delivers services, and develops solutions based on a proprietary grid ledger system to leverage blockchain technology in various business settings, including advertisement tracking, online visitor management, and sales of non-fungible tokens. The company's customers represent a diverse range of industries, such as information technology, shipping, real estate, entertainment, cosmetics, and chemical products.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.